Tibetan Medicine Classic Formula Srolo Bzhtang Granules Ameliorates Pulmonary Fibrosis via Dual Pathways of Nrf2/HO-1 and PI3K/AKT/mTOR Regulating Oxidative Stress
Abstract
Objective
To investigate how Srolo Bzhtang (SBT), a classical Tibetan medicine formula, improves oxidative stress and ultimately alleviates pulmonary fibrosis in rats through the Nrf2/HO-1 and PI3K/AKT/mTOR pathways.
Methods
Seventy-two SD rats were randomly assigned to 12 sham surgery groups (Sham group, receiving equal volumes of normal saline) and 60 model groups (established by intratracheal instillation of bleomycin to induce pulmonary fibrosis). Twenty-four hours after modeling, the model groups were randomly divided into the model group (Model), the positive drug group (pirfenidone, 150 mg/kg), and low, medium, and high dose Soroxisol groups (SBT-L 0.5 g/kg, SBT-M 1.5 g/kg, SBT-H 4.5 g/kg), with 12 rats in each group. Each group received the drug by gavage once daily for 21 days.The Sham and Model groups received equal volumes of normal saline. HE and Masson staining were used to observe the pathological changes of pulmonary fibrosis in each group. ELISA was used to measure the levels of inflammatory factors (TNF-α, IL-8) and matrix metalloproteinases (MMP-2, MMP-9) in serum. The activities of malondialdehyde (MDA) and superoxide dismutase (SOD) in serum were also measured. The expression levels of Nrf2/HO-1 and proteins in the PI3K/AKT/mTOR signaling pathway in lung tissue were determined by Western blot.
Results
HE and Masson staining showed that pulmonary fibrosis was more severe in the Model group than in the Sham group, and each drug administration group could reverse this process to varying degrees. SBT inhibited the levels of inflammatory factors TNF-α and IL-8 (all P < 0.05), and compared with the Model group, the levels of matrix metalloproteinases MMP-2 and MMP-9 were decreased (all P < 0.05). Pathological section results showed that SBT improved lung tissue damage in pulmonary fibrosis rats to some extent. Compared with the Model group, MDA levels in the low-, medium-, and high-dose SBT groups decreased (all P < 0.05), and SOD enzyme activity showed an increasing trend. Western blot results indicated that, compared with the Model group, the low-, medium-, and high-dose SBT groups activated the protein expression of Nrf2 and HO-1 (all P < 0.05) and downregulated the expression levels of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR (all P < 0.05).
Conclusion
SBT affects the Nrf2/HO-1 and PI3K/AKT/mTOR signaling pathways, inhibits oxidative stress, and thereby delays the progression of pulmonary fibrosis in rats.
Keywords: Tibetan Medicine Classic Formula, Srolo Bzhtang Granules, Pulmonary fibrosis, Oxidative stress, Mechanism pathway
Full Text:
PDFReferences
SHENG G, CHEN P, WEI Y, et al. Viral infection increases the risk of idiopathic pulmonary fibrosis: a meta-analysis. Chest, 2020, 157(5): 1175-1187. doi: 10.1016/j.chest.2019.10.032.
MOSS B J, RYTER S W, ROSAS I O. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol, 2022, 17: 515-546. doi: 10.1146/annurev-pathol-042320-030240.
MAHER T M, BENDSTRUP E, DRON L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res, 2021, 22(1): 197. doi: 10.1186/s12931-021-01791-z.
WANG S, ZHOU Q, TIAN Y, et al. The lung microbiota affects pulmonary inflammation and oxidative stress induced by PM2.5 exposure. Environ Sci Technol, 2022, 56(17): 12368-12379. doi: 10.1021/acs.est. 1c08888.
SAVIN I A, ZENKOVA M A, SEN’KOVA A V. Pulmonary fibrosis as a result of acute lung inflammation: molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches. Int J Mol Sci, 2022, 23(23): 14959. doi: 10.3390/ijms232314959.
FORMAN H J, ZHANG H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov, 2021, 20(9): 689-709. doi: 10.1038/s41573-021-00233-1.
SPAGNOLO P, KROPSKI J A, JONES M G, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther, 2021, 222: 107798. doi: 10.1016/j.pharmthera.2020.107798.
BENEGAS U M, RAMIREZ R J, SANCHEZ G M. Idiopathic pulmonary fibrosis. Radiologia (Engl Ed), 2022, 64 Suppl 3: 227-239. doi: 10.1016/j. rxeng.2022.10.009.
JING L, SU S, ZHANG D, et al. Srolo Bzhtang, a traditional Tibetan medicine formula, inhibits cigarette smoke induced airway inflammation and muc5ac hypersecretion via suppressing IL-13 /STAT6 signaling pathway in rats. J Ethnopharmacol, 2019, 235: 424-344. doi: 10.1016/j.jep. 2019.02.006.
CHEN T, SU S, YANG Z, et al. Srolo Bzhtang reduces inflammation and vascular remodeling via suppression of the MAPK/NF-κB signaling pathway in rats with pulmonary arterial hypertension. J Ethnopharmacol, 2022, 297: 115572. doi: 10.1016/j.jep.2022.115572.
BAO S L, LI Y F, DUAN Y B. et al. Effect of Tibetan medicine Siwei Lagencaitang powder on inflammatory factors in rats with myocardial ischemia-reperfusion injury. Western Journal of Traditional Chinese Medicine, 2021, 34(1): 52-54. doi: 10.12174/j.issn.2096-9600.2021.01.15.
LI S D, LI Y L, ZHANG H T. et al, Medication rule of TCM patent compound formula in treatment of pulmonary fibrosis based on data mining. Acta Chinese Medicine, 2025, 40(1): 50-56. doi: 10.16368/j.issn. 1674-8999.2025.01.009.
ZHANG J, ZHANG J Z, YAO Z Z, et al. GAMG ameliorates silica-induced pulmonary inflammation and fibrosis via the regulation of EMT and NLRP3/TGF-β1/Smad signaling pathway. Ecotoxicol Environ Saf, 2024, 285: 117124. doi: 10.1016/j.ecoenv.2024.117124.
ZENG Q, ZHOU T, ZHAO F Y. et al. p62-Nrf2 Regulatory loop mediates the anti-pulmonary fibrosis effect of bergenin. Antioxidants (Basel, Switzerland), 2022, 11(2): 307. doi: 10.3390/antiox11020307.
LI X, WANG Y, LIANG J, et al. Bergenin attenuates bleomycin-induced pulmonary fibrosis in mice via inhibiting TGF-β1 signaling pathway. Phytother Res, 2021, 35(10): 5808-5822. doi: 10.1002/ptr.7239.
KOLAHIAN S, FERNANDEZ I E, EICKELBERG O, et al. Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol, 2016, 55(3): 309-322. doi: 10.1165/rcmb.2016-0121TR.
LI R L, GU R, ZEWENGYONGZHONG, et al. Herbal textual research and usage status of Tibetan medicine “Suoluogabu”. Journal of Chengdu University of Traditional Chinese Medicine, 2023, 46(4): 62-68. doi: 10. 13593/j.cnki.51-1501/r.2023.04.062.
Editorial Committee. Chinese materia medica of Tibetan medical volume. Shanghai: Shanghai Science and Technology Press, 2002.
. ZAXIZHUOMA, TAWAJI, DANZHENJI, et al. Key information verification of the Suoluogabu. Chinese Traditional Patent Medicine, 2025, 47(8): 2670-2675. doi: 10.3969/j.issn.1001-1528.2025.08.029.
GLASS D S, GROSSFELD D, RENNA H A, et al. Idiopathic pulmonary fibrosis: current and future treatment. Clin Respir J, 2022, 16(2): 84-96. doi: 10.1111/crj.13466.
MURI J, DURCOVA B, SLIVKA R, et al. Idiopathic pulmonary fibrosis: review of current knowledge. Physiol Res, 2024, 73(4): 487-497. doi: 10. 33549/physiolres.935322.
WINSLOW C E. A new method of enumerating bacteria in air. Science, 1908, 28(705): 28-31. doi: 10.1126/science.28.705.28.
O'DWYE D N, ASHLEY S L, GURCZYNSKI S J, et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med, 2019, 199(9): 1127-1138. doi: 10.1164/rccm.201809-1650OC.
KOUDSTAAL T. et al. Pulmonary fibrosis: from pathogenesis to clinical decision-making. Trends Mol Med, 2023, 29(12): 1076-1087. doi: 10.1016/
Refbacks
- There are currently no refbacks.
